Cutting-Edge

Immunotherapy

To Treat Cancer

WHAT WE DO

Western Oncolytics develops novel therapies for cancer. We take cutting-edge treatments that show promise in early laboratory research and demonstrate their value to patients in clinical trials. We expect that our lead technology, a novel immuno-oncolytic therapy, can extend the lives of, or outright cure, patients across a wide range of cancer types, while avoiding the severe side effects common with current cancer therapies. Thus, we aim to use the most sophisticated science to give life and hope to cancer patients.

WO-12

ONCOLYTICS

With the advent of genetic engineering, viruses have been designed to infect only cancer cells while also delivering therapeutic genes. Several such therapies have demonstrated efficacy in randomized patient trials. This approach can be ideal for treating cancers that are spreading (metastic), and holds promise to be more effective and tolerable than any currently available therapy.

OUR TECHNOLOGY

Western Oncolytics’ lead therapy, WO-12, is designed to be both more effective and safer than other technologies in the field. It stimulates a more potent and directed immune attack against cancer, while removing blocks to immune activity in tumor environments. Further, it has redundant safety features, focusing activity on just tumors and potentially allowing for more of the therapy to be used throughout the body. Perhaps most importantly, WO-12 is designed to work across a range of solid tumor types (up to 85% of all cancers), and in combination with current therapies.

The graph on the left shows that a prototype of the WO-12 is more effective than an oncolytic currently in late clinical trials.  The graph on the right shows that our WO-12, shrinks tumors.

TEAM